Accelerate range

The best way to heal

  • Speeds up wound healing
  • Is cost-effective
  • Improves patients' quality of life

picto_prepare_nb picto_clean_nb picto_accelerate picto_close_nb






Leg ulcers, pressure ulcers and diabetic foot ulcers are common wound types and part of the day-to-day reality for healthcare professionals. In response to this problem, Urgo has developed the UrgoStart range which is clinically proven to accelerate the wound-healing process, once the wound is clean and prepared for healing.


Mode of action

TLC (Technology Lipido-Colloid) combined with NOSF (Nano-Oligo Saccharide Factor) is a patented innovative technology which in contact with wound exudate forms a gel and creates a moist environment enabling the key cells involved in the repair process (fibroblasts, keratinocyrtes, macrophages) to exert their action.

TLC-NOSF interacts with the wound micro-environment of the wound by preventing the detrimental effect of Matrix Metallo Proteases (MMPs) which in excess in chronic wounds creates a continuous degradation of the extra-cellular matrix. TLC-NOSF restores balance in the wound bed so granulation of chronic wounds can occur. UrgoStart thereby promotes faster wound healing.


TLC NOSF Technology



Leg ulcers, pressure ulcers, diabetic foot ulcers.




In order not to delay any optimal treatment, UrgoStart is contraindicated in wounds such as cancerous wounds or fistula wounds which may reveal a deep abscess.


Key benefits

  • Promotes faster healing (1)
  • Is cost-effective
  • Improves patients’ quality of life (1)





Clinical evidence

For a review of the clinical evidence for TLC-NOSF dressings please click here

(1) Meaume S, et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair and Regeneration 2012 (July/August);Vol 20:500-511.

Last update : January 21, 2021